Nektar Therapeutics (0UNL.L)
USD 0.84
(0.63%)
USD 0.84
(0.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 398.03 Million USD | -43.99% |
| 2022 | 710.6 Million USD | -36.39% |
| 2021 | 1.11 Billion USD | -27.4% |
| 2020 | 1.53 Billion USD | -22.18% |
| 2019 | 1.97 Billion USD | -8.04% |
| 2018 | 2.15 Billion USD | 322.54% |
| 2017 | 508.86 Million USD | -10.55% |
| 2016 | 568.87 Million USD | 13.31% |
| 2015 | 502.06 Million USD | 13.69% |
| 2014 | 441.62 Million USD | 1.63% |
| 2013 | 434.52 Million USD | -12.71% |
| 2012 | 497.79 Million USD | -17.93% |
| 2011 | 606.55 Million USD | 16.37% |
| 2010 | 521.22 Million USD | -9.43% |
| 2009 | 575.51 Million USD | 2.67% |
| 2008 | 560.53 Million USD | -22.7% |
| 2007 | 725.1 Million USD | -5.61% |
| 2006 | 768.17 Million USD | -10.53% |
| 2005 | 858.55 Million USD | 15.25% |
| 2004 | 744.92 Million USD | 20.77% |
| 2003 | 616.78 Million USD | 1.67% |
| 2002 | 606.63 Million USD | -9.08% |
| 2001 | 667.24 Million USD | 5.99% |
| 2000 | 629.54 Million USD | 177.57% |
| 1999 | 226.8 Million USD | 68.63% |
| 1998 | 134.49 Million USD | 12.3% |
| 1997 | 119.76 Million USD | 188.58% |
| 1996 | 41.5 Million USD | 78.88% |
| 1995 | 23.2 Million USD | 34.88% |
| 1994 | 17.2 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 343.33 Million USD | -13.3% |
| 2024 Q1 | 396.01 Million USD | -0.51% |
| 2023 Q2 | 494.27 Million USD | -12.01% |
| 2023 Q3 | 442.24 Million USD | -10.53% |
| 2023 Q4 | 398.03 Million USD | -10.0% |
| 2023 Q1 | 561.74 Million USD | -20.95% |
| 2023 FY | 398.03 Million USD | -43.99% |
| 2022 Q4 | 710.6 Million USD | -9.01% |
| 2022 Q1 | 1.02 Billion USD | -8.33% |
| 2022 FY | 710.6 Million USD | -36.39% |
| 2022 Q3 | 781 Million USD | -9.39% |
| 2022 Q2 | 861.98 Million USD | -15.83% |
| 2021 Q4 | 1.11 Billion USD | -12.53% |
| 2021 FY | 1.11 Billion USD | -27.4% |
| 2021 Q1 | 1.45 Billion USD | -5.34% |
| 2021 Q2 | 1.37 Billion USD | -5.85% |
| 2021 Q3 | 1.27 Billion USD | -6.86% |
| 2020 Q4 | 1.53 Billion USD | 2.0% |
| 2020 Q2 | 1.59 Billion USD | -15.52% |
| 2020 Q3 | 1.5 Billion USD | -5.41% |
| 2020 Q1 | 1.88 Billion USD | -4.52% |
| 2020 FY | 1.53 Billion USD | -22.18% |
| 2019 Q4 | 1.97 Billion USD | -5.31% |
| 2019 FY | 1.97 Billion USD | -8.04% |
| 2019 Q1 | 2.16 Billion USD | 0.76% |
| 2019 Q2 | 2.09 Billion USD | -3.08% |
| 2019 Q3 | 2.08 Billion USD | -0.54% |
| 2018 Q4 | 2.15 Billion USD | -4.4% |
| 2018 Q1 | 496.79 Million USD | -2.37% |
| 2018 Q3 | 2.24 Billion USD | -2.77% |
| 2018 FY | 2.15 Billion USD | 322.54% |
| 2018 Q2 | 2.31 Billion USD | 365.61% |
| 2017 Q1 | 528.48 Million USD | -7.1% |
| 2017 FY | 508.86 Million USD | -10.55% |
| 2017 Q4 | 508.86 Million USD | -12.57% |
| 2017 Q3 | 582.05 Million USD | 22.32% |
| 2017 Q2 | 475.85 Million USD | -9.96% |
| 2016 Q3 | 425.09 Million USD | -8.21% |
| 2016 FY | 568.87 Million USD | 13.31% |
| 2016 Q2 | 463.09 Million USD | -5.85% |
| 2016 Q1 | 491.87 Million USD | -2.03% |
| 2016 Q4 | 568.87 Million USD | 33.82% |
| 2015 FY | 502.06 Million USD | 13.69% |
| 2015 Q1 | 499.21 Million USD | 13.04% |
| 2015 Q2 | 456.66 Million USD | -8.52% |
| 2015 Q3 | 449.24 Million USD | -1.63% |
| 2015 Q4 | 502.06 Million USD | 11.76% |
| 2014 Q3 | 476.9 Million USD | -0.26% |
| 2014 Q2 | 478.13 Million USD | -1.82% |
| 2014 Q1 | 487.01 Million USD | 12.08% |
| 2014 Q4 | 441.62 Million USD | -7.4% |
| 2014 FY | 441.62 Million USD | 1.63% |
| 2013 Q3 | 383.03 Million USD | -7.21% |
| 2013 Q1 | 447.9 Million USD | -10.02% |
| 2013 Q4 | 434.52 Million USD | 13.44% |
| 2013 FY | 434.52 Million USD | -12.71% |
| 2013 Q2 | 412.8 Million USD | -7.83% |
| 2012 Q1 | 694.78 Million USD | 14.55% |
| 2012 FY | 497.79 Million USD | -17.93% |
| 2012 Q4 | 497.79 Million USD | -8.06% |
| 2012 Q3 | 541.45 Million USD | -19.0% |
| 2012 Q2 | 668.44 Million USD | -3.79% |
| 2011 Q1 | 704.47 Million USD | 35.16% |
| 2011 FY | 606.55 Million USD | 16.37% |
| 2011 Q4 | 606.55 Million USD | -6.41% |
| 2011 Q3 | 648.09 Million USD | -3.39% |
| 2011 Q2 | 670.85 Million USD | -4.77% |
| 2010 Q1 | 548.5 Million USD | -4.69% |
| 2010 FY | 521.22 Million USD | -9.43% |
| 2010 Q3 | 502.47 Million USD | -5.31% |
| 2010 Q2 | 530.63 Million USD | -3.26% |
| 2010 Q4 | 521.22 Million USD | 3.73% |
| 2009 Q4 | 575.51 Million USD | 27.14% |
| 2009 Q2 | 472.99 Million USD | -6.51% |
| 2009 FY | 575.51 Million USD | 2.67% |
| 2009 Q1 | 505.93 Million USD | -9.74% |
| 2009 Q3 | 452.65 Million USD | -4.3% |
| 2008 Q1 | 643.83 Million USD | -11.21% |
| 2008 FY | 560.53 Million USD | -22.7% |
| 2008 Q2 | 609.49 Million USD | -5.33% |
| 2008 Q3 | 568.35 Million USD | -6.75% |
| 2008 Q4 | 560.53 Million USD | -1.38% |
| 2007 Q4 | 725.1 Million USD | -1.79% |
| 2007 FY | 725.1 Million USD | -5.61% |
| 2007 Q1 | 713.74 Million USD | -7.09% |
| 2007 Q2 | 703.46 Million USD | -1.44% |
| 2007 Q3 | 738.28 Million USD | 4.95% |
| 2006 FY | 768.17 Million USD | -10.53% |
| 2006 Q1 | 841.53 Million USD | -1.98% |
| 2006 Q4 | 768.17 Million USD | -2.76% |
| 2006 Q3 | 790.02 Million USD | -4.49% |
| 2006 Q2 | 827.14 Million USD | -1.71% |
| 2005 Q4 | 858.55 Million USD | -9.33% |
| 2005 Q1 | 714.19 Million USD | -4.13% |
| 2005 FY | 858.55 Million USD | 15.25% |
| 2005 Q2 | 694.05 Million USD | -2.82% |
| 2005 Q3 | 946.91 Million USD | 36.43% |
| 2004 Q2 | 760.91 Million USD | -3.33% |
| 2004 FY | 744.92 Million USD | 20.77% |
| 2004 Q4 | 744.92 Million USD | 0.52% |
| 2004 Q3 | 741.1 Million USD | -2.6% |
| 2004 Q1 | 787.13 Million USD | 27.62% |
| 2003 Q4 | 616.78 Million USD | -2.55% |
| 2003 Q3 | 632.92 Million USD | -0.25% |
| 2003 Q2 | 634.49 Million USD | 12.51% |
| 2003 Q1 | 563.94 Million USD | -7.04% |
| 2003 FY | 616.78 Million USD | 1.67% |
| 2002 Q4 | 606.63 Million USD | -3.18% |
| 2002 Q2 | 657 Million USD | -3.49% |
| 2002 Q1 | 680.78 Million USD | 2.03% |
| 2002 Q3 | 626.53 Million USD | -4.64% |
| 2002 FY | 606.63 Million USD | -9.08% |
| 2001 Q3 | 685.68 Million USD | -5.12% |
| 2001 Q4 | 667.24 Million USD | -2.69% |
| 2001 FY | 667.24 Million USD | 5.99% |
| 2001 Q1 | 687.14 Million USD | 9.15% |
| 2001 Q2 | 722.69 Million USD | 5.17% |
| 2000 Q2 | 434.36 Million USD | -3.11% |
| 2000 Q4 | 629.54 Million USD | 49.77% |
| 2000 Q1 | 448.29 Million USD | 97.65% |
| 2000 Q3 | 420.32 Million USD | -3.23% |
| 2000 FY | 629.54 Million USD | 177.57% |
| 1999 Q2 | 126.68 Million USD | -3.55% |
| 1999 Q3 | 121.36 Million USD | -4.2% |
| 1999 Q4 | 226.8 Million USD | 86.87% |
| 1999 FY | 226.8 Million USD | 68.63% |
| 1999 Q1 | 131.34 Million USD | -2.34% |
| 1998 Q4 | 134.49 Million USD | 31.09% |
| 1998 Q2 | 110.06 Million USD | -3.34% |
| 1998 FY | 134.49 Million USD | 12.3% |
| 1998 Q1 | 113.87 Million USD | -4.92% |
| 1998 Q3 | 102.59 Million USD | -6.78% |
| 1997 Q4 | 119.76 Million USD | 60.01% |
| 1997 Q1 | 73.01 Million USD | 75.94% |
| 1997 FY | 119.76 Million USD | 188.58% |
| 1997 Q2 | 74.8 Million USD | 2.44% |
| 1997 Q3 | 74.84 Million USD | 0.06% |
| 1996 Q3 | 36.8 Million USD | -4.91% |
| 1996 FY | 41.5 Million USD | 78.88% |
| 1996 Q1 | 21.2 Million USD | -8.62% |
| 1996 Q4 | 41.5 Million USD | 12.77% |
| 1996 Q2 | 38.7 Million USD | 82.55% |
| 1995 FY | 23.2 Million USD | 34.88% |
| 1995 Q1 | 28.5 Million USD | 65.7% |
| 1995 Q2 | 26.7 Million USD | -6.32% |
| 1995 Q3 | 25 Million USD | -6.37% |
| 1995 Q4 | 23.2 Million USD | -7.2% |
| 1994 FY | 17.2 Million USD | 0.0% |
| 1994 Q3 | 20.3 Million USD | -2.87% |
| 1994 Q4 | 17.2 Million USD | -15.27% |
| 1994 Q1 | 7.1 Million USD | 0.0% |
| 1994 Q2 | 20.9 Million USD | 194.37% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 52.142% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 57.526% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 48.831% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -140.498% |
| bluebird bio, Inc. | 619.16 Million USD | 35.714% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -216.291% |
| Imunon, Inc. | 21.91 Million USD | -1716.004% |
| Editas Medicine, Inc. | 499.15 Million USD | 20.258% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 98.508% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 88.138% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 66.795% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 87.758% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 71.75% |
| Verastem, Inc. | 149.71 Million USD | -165.855% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.509% |
| Waters Corporation | 4.62 Billion USD | 91.397% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.597% |
| Biogen Inc. | 26.84 Billion USD | 98.517% |
| Perrigo Company plc | 10.8 Billion USD | 96.318% |
| Dynavax Technologies Corporation | 997.09 Million USD | 60.081% |
| Illumina, Inc. | 10.11 Billion USD | 96.063% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1307.85% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 48.993% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -78.886% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -505.926% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 94.182% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -140.765% |
| Evolus, Inc. | 188.99 Million USD | -110.602% |
| Adicet Bio, Inc. | 207.29 Million USD | -92.013% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -101.633% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.797% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -93.411% |
| FibroGen, Inc. | 423.52 Million USD | 6.02% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 96.302% |
| OPKO Health, Inc. | 2.01 Billion USD | 80.214% |
| Homology Medicines, Inc. | 47.05 Million USD | -745.853% |
| Geron Corporation | 394.07 Million USD | -1.004% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 89.607% |
| Exelixis, Inc. | 2.94 Billion USD | 86.472% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -8.017% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -157.817% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 69.405% |
| Zoetis Inc. | 14.28 Billion USD | 97.214% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 32.334% |
| Abeona Therapeutics Inc. | 64 Million USD | -521.907% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.249% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -611.421% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 86.688% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 87.808% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 35.958% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 77.036% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 62.065% |
| Insmed Incorporated | 1.32 Billion USD | 70.069% |
| TG Therapeutics, Inc. | 329.58 Million USD | -20.767% |
| Incyte Corporation | 6.78 Billion USD | 94.131% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 78.308% |